Tag: HIF-2α inhibitor therapy

Home / HIF-2α inhibitor therapy

Categories

Belzutifan is approved by USFDA for advanced renal cell carcinoma

The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell carcinoma (RCC) who have previously recei...
hif-2%ce%b1-inhibitor-therapy

Scan the code